Ravidasvir

From WikiProjectMed
Jump to navigation Jump to search
Ravidasvir
Ravidasvir.svg
Names
Other namesPPI-668
  • (2S)-2-{[Hydroxy(methoxy)methylidene]amino}-1-[(2S)-2-[5-(6-{2-[(2S)-1-[(2S)-2-{[hydroxy(methoxy)methylidene]amino}-3-methylbutanoyl]pyrrolidin-2-yl]-1H-1,3-benzodiazol-6-yl}naphthalen-2-yl)-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methylbutan-1-one
Clinical data
Drug classNS5A inhibitor[1]
Main usesHepatitis C[2]
Side effectsGenerally minor, low blood sugar[3]
Routes of
use
By mouth[2]
Chemical and physical data
FormulaC42H50N8O6
Molar mass762.912 g·mol−1
3D model (JSmol)
  • CC(C)[C@@H](C(=O)N1CCC[C@H]1C2=NC3=C(N2)C=C(C=C3)C4=CC5=C(C=C4)C=C(C=C5)C6=CN=C(N6)[C@@H]7CCCN7C(=O)[C@H](C(C)C)NC(=O)OC)NC(=O)OC
  • InChI=1S/C42H50N8O6/c1-23(2)35(47-41(53)55-5)39(51)49-17-7-9-33(49)37-43-22-32(46-37)29-14-13-25-19-26(11-12-27(25)20-29)28-15-16-30-31(21-28)45-38(44-30)34-10-8-18-50(34)40(52)36(24(3)4)48-42(54)56-6/h11-16,19-24,33-36H,7-10,17-18H2,1-6H3,(H,43,46)(H,44,45)(H,47,53)(H,48,54)/t33-,34-,35-,36-/m0/s1
  • Key:LCHMHYPWGWYXEL-ZYADHFCISA-N

Ravidasvir is a medication used to treat hepatitis C.[2] It is typically used together with sofosbuvir with a 97% cure rate.[4] It can be used in people infected with both hepatitis C and HIV/AIDS.[4] It is taken by mouth.[2]

Side effects are generally minor.[3] In people with diabetes, low blood sugar may occur.[3] In those who also have hepatitis B reactivation may occur.[3] It is a NS5A inhibitor.[1]

Ravidasvir was approved for medical use in Malaysia and Egypt in 2021.[4] It is on the World Health Organization's List of Essential Medicines.[5] A 12 week course of treatment is expected to cost about 300 to 500 USD.[1]

History

Preliminary clinical trial results were announced in Nov 2015.[6] In April 2017, press reports stated that a combination treatment involving ravidasvir and sofosbuvir had achieved a 97% clearup rate against hepatitis C in a clinical trial conducted in Malaysia and Thailand, and 100% in another conducted in Egypt.[7] It has been granted conditional registration by the National Pharmaceutical Regulatory Agency (NPRA) of Malaysia.[8][9]

References

  1. 1.0 1.1 1.2 "First hepatitis C treatment developed through South-South cooperation registered in Malaysia | DNDi". dndi.org. 14 June 2021. Archived from the original on 7 April 2023. Retrieved 10 September 2023.
  2. 2.0 2.1 2.2 2.3 "eEML - Electronic Essential Medicines List". list.essentialmeds.org. Archived from the original on 10 September 2023. Retrieved 10 September 2023.
  3. 3.0 3.1 3.2 3.3 "24th WHO Expert Committee on Selection and Use of Essential Medicines Expert review" (PDF). WHO. WHO. Archived (PDF) from the original on 10 September 2023. Retrieved 10 September 2023.
  4. 4.0 4.1 4.2 "Ravidasvir + sofosbuvir | DNDi". dndi.org. 31 December 2015. Archived from the original on 21 May 2023. Retrieved 10 September 2023.
  5. World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.
  6. "Good Results for Sovaldi and Ravidasvir Treating Hepatitis C Genotype 4". Hepatitis Magazine. November 24, 2015. Archived from the original on June 4, 2023. Retrieved August 16, 2023.
  7. Kollewe J (13 April 2018). "Non-profit's $300 hepatitis C cure as effective as $84,000 alternative". The Guardian. Archived from the original on 25 May 2023. Retrieved 16 August 2023.
  8. "List of new products approved by the National Pharmaceutical Regulatory Agency (NPRA) of Malaysia" (PDF). Archived (PDF) from the original on 2022-08-08. Retrieved 2023-08-16.
  9. "First hepatitis C treatment developed through South-South cooperation registered in Malaysia | DNDi". dndi.org. 2021-06-14. Archived from the original on 2021-08-10. Retrieved 2021-08-10.

External links

Identifiers: